Ask AI
ProCE Banner Activity

VOLITION: Interim Analysis From Phase IIIb Trial of Optional Switch to LA CAB + RPV Following ART Initiation on DTG/3TC

Conference Coverage
Slideset

In the phase IIIb VOLITION study, ART initiation with dolutegravir/lamivudine (DTG/3TC) resulted in rapid virologic suppression, allowing ART-naive participants with HIV the option to switch to long-acting ART.

Released: July 17, 2025

Expiration: January 16, 2026

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare

Partners

IAS

ProCE Banner